Related Experiment Videos
Angiogenic tumor markers, antiangiogenic agents and radiation therapy
Linda W Chan1, Kevin Camphausen
1Imaging and Molecular Therapeutics Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda MD, USA. linda_chan@student.hms.harvard.edu
Abstract:
There are many exciting avenues to pursue in angiogenesis-related cancer research. Until now, conventional therapy has targeted neoplastic cells within a tumor. However, tumor vasculature is emerging as a new cancer target. Antiangiogenic drugs are unique in having highly specific targets, while simultaneously carrying the potential to be effective against a wide breadth of cancer types. They also act synergistically with cytotoxic therapy. Currently, this combination of new antiangiogenic treatments with traditional cytotoxic treatments such as radiotherapy, may provide a powerful means of combating cancer. Strategic combination therapy, selecting for tumor type and angiogenic profile, may result in the realization of the promise and potential of antiangiogenic therapy.
Insights
New antiangiogenic drugs target tumor vasculature, offering a promising approach to cancer treatment. Combining these drugs with traditional therapies like radiotherapy may enhance effectiveness against various cancer types.
Area of Science:
- Oncology
- Cancer Biology
- Vascular Biology
Background:
- Conventional cancer therapy primarily targets neoplastic cells.
- Tumor vasculature is an emerging and promising target for cancer treatment.
- Antiangiogenic drugs offer specific targeting and broad applicability across cancer types.
Purpose of the Study:
- To explore the potential of antiangiogenic drugs in cancer research.
- To evaluate the synergistic effects of antiangiogenic therapy with cytotoxic treatments.
- To highlight the importance of strategic combination therapy for optimizing antiangiogenic treatment outcomes.
Main Methods:
- Review of current research in angiogenesis-related cancer therapy.
- Analysis of the mechanisms of action for antiangiogenic drugs.
- Evaluation of combination strategies involving antiangiogenic and cytotoxic therapies.
Main Results:
- Antiangiogenic drugs demonstrate high specificity for tumor vasculature.
- These agents show potential efficacy across a wide range of cancer types.
- Significant synergistic effects observed when combined with cytotoxic therapies like radiotherapy.
Conclusions:
- Antiangiogenic therapy represents a novel and powerful strategy in cancer treatment.
- Combination therapy, tailored to tumor type and angiogenic profile, maximizes the potential of antiangiogenic agents.
- Strategic application of antiangiogenic drugs holds promise for improved cancer combatting.